Proteasome inhibitor


Nuclear factor-kappa B pathway and response in a phase II trial of borte- zomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (Chung et al. 2010). Twenty-one of 25 enrolled patients were assessable for response; one partial response (PR, 5%), 10 stable disease (SD, 48%) and 10 progressive disease (PD, 48%). Patients with PR/SD had significantly longer survival compared with patients with PD and the regimen was well tolerated. Only one of 20 tumors was positive for HPV. Patients with PD had higher expression of NF-kappaB and epidermal growth factor receptor-associated genes in their tumors by gene expression analysis.

Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group (Gilbert et al. 2013). The response rate of bortezomib and irinotecan was 13%. One patient had a partial response to borte- zomib alone (response rate 3%). No responses were seen in patients with addition of irinotecan at time of progression on bortezomib.

< Prev   CONTENTS   Source   Next >